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A 42-year-old man with a cardiac tamponade underwent an urgent pericardiotomy that showed tumoral tissue, covering the
surface of the right atrium. The tumor was then partially excised, and the histological examination revealed the presence of a
moderately-diﬀerentiated angiosarcoma. The patient was then referred to the oncology unit and scheduled for a chemotherapy
schedule including Epirubicin (60mg/m2, on days 1 and 2) plus Ifosfamide (2000mg/m2,o nd a y s1t o3 )a n dU r o m i t e x a n
(2000mg/m2 at hours 0, 4, 8 after IFO). All drugs were administered every three weeks. After two cycles, a restaging work-up
revealed a partial remission. The treatment was continued for another two cycles. A new evaluation by cardiac MRI evidenced a
localanddistant(lung)progressionofdisease.Thepatientdiedafterthreemonths.Thispaperconﬁrmsthatcardiacangiosarcoma
is a fatal disease, and the prognosis is usually 6–11 months from time of diagnosis.
Copyright © 2009 L. Antonuzzo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.CaseReport
A 42-year-old man with a cardiac tamponade was referred
to the Department of Cardiovascular Surgery of our hospital
to be submitted to an urgent pericardiotomy following
a median sternotomy. His medical history dated back to
July 2006 when he was admitted to the Cardiological
Department of General Hospital in a suburb of Florence,
complaining of a three-week history of chest pain and
dyspnea. On admission, the patient was in good general
condition. Blood pressure (BP) and pulse were normal.
Heart auscultation was unremarkable except for a faint
pericardial rub; chest examination showed normal breath
sounds. Blood tests showed hemoglobin 11.5g/dl, leukocyte
count 7000/mm3, platelet count 250 × 103/mm3;l i v e r
and renal biochemistry, clotting proﬁle, and erythrocyte
sedimentation rate (ESR) were normal. At this time chest
X-ray showed a mild cardiomegaly. An electrocardiogram
(EKG) showed normal sinus rhythm without acute ischemic
alterations. Subsequently, he was submitted to transthoracic
echocardiography (TTE) that documented a voluminous
pericardial eﬀusion with normal left ventricular function.
The patient was treated with pericardiocentesis, and a total
of 1500cc of hemorrhagic pericardial ﬂuid was aspirated.
Laboratory and cytological analysis of the pericardial ﬂuid
resulted negative for malignancy. After a complete diagnostic
work-up he was diagnosed as having acute pericarditis
(of likely viral origin) and he was discharged in good
condition from the hospital for follow-up and ambulatory
investigation. A month after discharge, the patient returned
to the emergency room of our hospital with a second episode
of chest pain, rapidly progressive dyspnea, hypotension,
and tachycardia. The TTE conﬁrmed the clinical suspect
of recurrent pericardial eﬀusion complicated by a cardiac
tamponade. Then it was necessary to again perform an
emergency pericardiocentesis with aspiration of 70cc alone
of hemorrhagic pericardial ﬂuid and to refer the patient
to the Department of Cardiovascular Surgery. The patient
underwent an urgent operation consisting in a median
sternotomy and longitudinal pericardiotomy. During the
operation a tumoral tissue was found covering the surface of
the right atrium and most of the anterolateral pericardium.
The tumor was then partially excised. The histological exam-
ination revealed the presence of a moderately diﬀerentiated
angiosarcoma.Thehistologicalfeaturesoftheneoplasmwere
quite variable among the diﬀerent zones of the lesion. At2 Case Reports in Medicine
low power, the tumor showed an alternation of hyper- and
hypocellular areas with the presence of dense keloid-type
collagen alternating to myxoid areas (Figure 1(a)). Due to
these features, on frozen section examination, the hypothesis
of solitary ﬁbrous tumor was raised. In areas, the tumor was
virtuallyavascularandcomposedofcompactmassesofmod-
erately pleomorphic spindled and epithelioid cells within a
collagenous stroma. In other areas, the neoplasm showed
clusters of small and short capillary-like slits, sometimes
in stellate conﬁguration, lined with variably atypical tumor
cells (Figure 1(b)). In other portions, the tumor displayed
large, well-formed, but irregularly contoured vascular spaces
in continuity with small sinusoidal-type tributaries or a
relatively pure sinusoidal vascular pattern, often intersected
by broad collagenous bands. The immunohistochemical
investigation documented that tumor cells were positive for
CD31 (Figure 1(c)), CD34 (Figure 1(d)), Von Willebrand
Factor (VWF) (Figure 1(e)), and about 60% of them were
positive for Mib-1 (Figure 1(f)), whereas they were negative
for EMA, bcl-2, smooth muscle actin, common muscle
actin, desmin, and protein S-100. The patient was moved
to the Department of Internal Medicine in our hospital. At
that time, hemodynamic parameters were stable, chest X-
ray showed cardiomegaly and left-sided pleural eﬀusion and
TTE detected only a small pericardial eﬀusion with normal
cardiac size and ventricular function (ejection fraction,
evaluated with TTE, was 63%). A further evaluation with
cardiac magnetic resonance imaging (MRI) showed a large
mass (53mm) extending from the free wall of the right
atrium to the anterior mediastinum beside the superior vena
cava and ascending aorta, above up to the right pulmonary
artery, clearly revealed irregular signals in the mass after
gadolinium enhancement (Figure 2). The extensive study
using computed tomography (CT) of the brain, chest
and abdomen and positron emission tomography (PET)
showed no metastasis. The patient was then referred to
our oncology unit and scheduled for a chemotherapeutic
regimen including Epirubicin (EPI) (60mg/m2,o nd a y s1
and 2) plus Ifosfamide (IFO) (2000mg/m2,o nd a y s1t o3 )
and Uromitexan (2000mg/m2 at hours 0, 4, 8 after IFO). All
drugs were administered every three weeks. After two cycles,
a restaging work-up with CT plus PET and cardiac MRI
revealed a partial response. The treatment was well tolerated
and continued for another two cycles. A new evaluation by
cardiac MRI and total body CT evidenced a local progression
of disease and appearance of pulmonary metastases. The
patient died after three months for occurrence of acute
respiratory failure.
2. Discussion
Primary tumors of the heart are extremely rare, occurring
at a frequency of 0.02% in autopsy series and the majority
of them are benign [1]. Metastatic heart tumors are 20–
40 times more frequent than primary cardiac tumors [2].
Statistically, heart cancer is listed with all cancers of the
soft tissues. In a report of 12487 consecutive autopsies,
only seven cases of primary cardiac tumor were reported,
most of which were benign [3]. Malignant tumors of the
heart are most often sarcoma (76–78%) and angiosarcoma,
the most aggressive histotype, accounts for about 31% of
all primary cardiac malignant tumors [4–8]. There are also
many other malignant subtypes including rhabdomyosar-
coma, malignant ﬁbrous histiocytoma, undiﬀerentiated and
ﬁbrosarcoma[9].Commonageofpresentationisthethirdto
ﬁfth decade and is more frequent in male (ratio male/female:
2-3/1). An angiosarcoma of the heart is considered primary
if there is no evidence of previous or concomitant tumors in
the soft tissue, bone, or subcutaneous tissue [10]. Angiosar-
coma of the heart usually involves the right atrium, and it
is characterized by a rapid and inﬁltrating growth within
the myocardial wall, friability, and tendency toward bleeding
[11].Infacttheclinicalpresentationwithpericardialeﬀusion
and cardiac tamponade is frequent. Another life-threatening
clinical presentation is the myocardial rupture due to tumor
inﬁltration and necrosis of the wall [12]. Clinical presenta-
tion of the cardiac sarcoma is usually late and dependent on
the eﬀect of the local inﬁltration within the cardiac wall, the
atrioventricular valves, the pericardium or the superior or
inferior vena cava or from symptoms or signs secondary to
the metastases.
The right atrium is the most common site of origin
followed by the left atrium, right ventricle, and left ventricle.
Unexplained chest pain, hemoptysis, clubbing, anemia,
cardiomegaly, or metastatic manifestations may be the ﬁrst
clue to these rare yet devastating entities. Tachycardia,
hypotension, pulsusparadoxus, andcongestionofneckveins
are hallmarks of pericardial eﬀusion. Electrocardiogram may
sometimes evidence arhythmia, conduction abnormalities,
or low voltage complexes but the screening tool of choice
for cardiac tumors is echocardiography which can detect an
intracavitary mass, pericardial eﬀusion, or a reduced pump
function. Cardiac RMI or a transesophagael echocardiogram
(TEE) is indicated to better deﬁne the exact location, the
size, and the locoregional extension of cardiac neoplasm
in absence of echocardiographic signiﬁcant signs. TEE has
a higher resolution (1–3mm) than MRI (5–10mm), while
MRI is better to identify tissue composition with ability to
diﬀerentiate solid, liquid, hemorrhagic and fatty structure.
Pericardial ﬂuid cytology is positive in 75–87% of patients.
However, pericardial biopsies guided by pericardioscopy
have a diagnostic value of 93.3–97%. A less invasive proce-
dure is the transvenous endocardial biopsy but it often false-
negative [13, 14]. Chest X-ray often evidence cardiomegaly,
pulmonary congestion, or pericardial eﬀusion. CT is useful
not only to better deﬁne local extent of the tumor, but also to
evidence possible metastasis quite frequent in angiosarcoma
(80%)especiallylungmetastasis.Thediﬀerentialdiagnosisis
very broad and must include thrombus, vegetation, foreign
body, intracardiac metastases, infectious and nonbacterial
thrombotic or marantic endocarditis [15], coronary artery
disease, constrictive cardiomyopathy, and bronchogenic car-
cinoma or mesothelioma [16]. Despite the availability of
modernimagine techniquesthediagnosis ofcardiacsarcoma
isusuallylate.Theprognosisofcardiacangiosarcomaispoor
with a median survival ranging from 6 to 11 months. The
therapy for primary cardiac tumors is still controversial butCase Reports in Medicine 3
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Figure 1: (a) (colouring H&E 10×) Angiosarcoma moderately diﬀerentiated. (b) (colouring H&E 40×) Greater enlargement
angiosarcoma moderately diﬀerentiated. (c) (20×) Immunohistochemical investigation tumor cells were positive for CD 31. (d) (20×)
Immunohistochemical investigation tumor cells were positive for CD34. (e) (20×) Immunohistochemical investigation tumor cells were
positive for FVIII rAg. (f) (40×) Positive for Mib-1 60%.
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Figure 2: Voluminous left pleural eﬀusion. Large mass extending from the free wall of the right atrium to the anterior mediastinum beside
the superior vena cava and ascending aorta and above until the right pulmonary artery.
the surgery represents the therapy of choice in the cases of
localized disease and is conditioned by the site of tumor
and by the frequent presence of metastases. The survival
percentage in patients treated with surgery ranges from 2
to 55 months with a median survival of 14 months. Despite
adverse prognostic data, there are reported cases of patients
with angiosarcoma and treated with only partial resection
followed by chemotherapy and radioteraphy who survived
34 or even 53 months [17, 18]. These long-term survivors
were submitted to extensive surgical resection of the primary
tumor, plus adjuvant multidisciplinary therapy and had
absence of systemic disease at the time of diagnoses [18].
From these case reports we should consider chemotherapy
and/or radiotherapy as adjuvant good options, after radical
ordebulkingsurgery,inordertoimprovetheoverallsurvival.
In this case we used a combination of Ifosfamide and
Epirubicin that is the most active treatment in sarcoma.
Most frequently used in literature are the combinations of4 Case Reports in Medicine
Cyclophosphamide, Doxorubicin, Vincristine, Dacarbazine
(CyVADIC), and of Dacarbazine or Mitomycin-C, Dox-
orubicin, Cisplatin, and Vincristine [19]. Sinatra et al.
reported that the combination of surgical resection and
radiation can reduce the mass and eliminate symptoms
despite an incomplete resection [20]. Radiation is limited to
the concern for cardiotoxicity [21]. Kakizaki et al. reported
a case of cardiac angiosarcoma treated with combination of
chemotherapy and immunotherapy (Interleukin-2) with a
survival of 30 months after surgery [22].
Cardiac transplant has been performed in some cases
with early diagnosis and cardiac tumor not completely
resectable but with worsened results because the immuno-
suppressive therapy can increase the risk of progression of
cancer disease [23, 24].
In conclusion primary cardiac angiosarcoma is a fatal
disease, and the prognosis is usually short (6–11 months);
chemotherapy has a soft impact on prognosis [25].
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